- Conditions
- Netherton Syndrome
- Interventions
- QRX003, 4% Lotion
- Drug
- Lead sponsor
- Quoin Pharmaceuticals
- Industry
- Eligibility
- 14 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Ichthyosis, Netherton Syndrome
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 1 Year to 60 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • New York, New York
- Conditions
- Netherton Syndrome
- Interventions
- QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BID
- Drug
- Lead sponsor
- Quoin Pharmaceuticals
- Industry
- Eligibility
- 14 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 2 more
- Conditions
- Netherton Syndrome
- Interventions
- DS-2325a, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Netherton Syndrome
- Interventions
- DS-2325a, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Netherton Syndrome
- Interventions
- QRX003, 4% Lotion
- Drug
- Lead sponsor
- Quoin Pharmaceuticals
- Industry
- Eligibility
- 14 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 1 more
- Conditions
- Netherton Syndrome
- Interventions
- Not listed
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- Not listed
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Rancho Santa Margarita, California • Chicago, Illinois • Philadelphia, Pennsylvania
- Conditions
- Netherton Syndrome
- Interventions
- ATR12-351
- Drug
- Lead sponsor
- Azitra Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Palo Alto, California • New Haven, Connecticut
- Conditions
- Netherton Syndrome
- Interventions
- BCX17725, Placebo
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Palo Alto, California • San Diego, California • New Haven, Connecticut + 2 more
- Conditions
- Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis, Congenital Ichthyosiform Erythroderma, Epidermolytic Ichthyosis, Netherton Syndrome
- Interventions
- Secukinumab, Placebo
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York
- Conditions
- Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
- Interventions
- BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, BPR277
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • St Louis, Missouri • Fargo, North Dakota
- Conditions
- Netherton Syndrome
- Interventions
- Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection, Placebo matching to spesolimab - solution for injection
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Rancho Santa Margarita, California • New Haven, Connecticut • Charleston, South Carolina + 1 more
- Conditions
- Netherton Syndrome
- Interventions
- Pimecrolimus 1% Cream
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Netherton Syndrome
- Interventions
- QRX003
- Drug
- Lead sponsor
- Quoin Pharmaceuticals
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Fremont, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more